Procedural aspects and use of AADs
| Author (year) | Ablation procedure | Number of procedures | Use of AADs after blanking |
|---|---|---|---|
| Liu et al (2005)14 | PVI | 1.3 Second procedure: 25% (1) | Oral amiodarone in one patient (25%) to prevent AT relapses after second procedure |
| Kilicaslan et al (2006)15 | PVI | 1.3 Second procedure: 25.9% (7) | 5 of 13 patients (38.5%) with relapse after the first procedure remained in SR on AADs 1 out of 2 patients with relapse after the second procedure remained in SR on AADs |
| Gaita et al (2007)16 | PVI+roof line+mitral isthmus | 1.2 Second procedure: 19.2% (5) | 10 of 16 patients (62.5%) in SR were off AADs |
| Bunch et al (2008)17 | Ostial PVI in 15 patients+roof line and mitral isthmus in seven patients WACA+roof line and mitral isthmus in 18 patients | 1.4 Second procedure: 39% (13) | Of the 78% patients in SR at 1 year, 14% were under AADs Of the 74% patients in SR at 3 years, 27% were under AADs |
| Di Donna et al (2010)18 | PVI+roof line+mitral isthmus+CTI (under fluoroscopic guidance in 15 patients) | 1.5 Second procedure: 52% | 11 of 17 patients (64.7%) in SR after the first procedure were on AADs 11 of 24 patients (45.8%) in SR after the second procedure were on AADs |
| McCready et al (2011)19 | PVI± roof line, mitral isthmus and CFAE ablation at the discretion of the operator | HCM 1.5; controls 1.3 Second procedure: 71.4% (10) HCM Third procedure: 14.3% (2) HCM Fourth procedure: 7.1% (1) HCM | The two patients with HCM in SR after catheter ablation were on AADs |
| Derejko et al (2013)20 | Ostial PVI+CTI line ± mitral isthmus, roof line and CFAE ablation at the discretion of the operator | 1.4 Second procedure: 43% (13) | 16 patients with no AF/AT relapse at 12 months were under AADs and these were stopped in five patients |
| Santangeli et al (2013)21 | All patients: PVI+posterior wall isolation between PVs+SVC isolation Persistent AF: +all posterior wall (CS and left side of septum)+CFAE (LA and CS) Redo: +non-PV triggers | 1.6±0.7 Second procedure: 58% (25) (All patients with recurrence) | 91% of patients in SR at 12 months, but only 76% off ADDs |
| Yan et al (2013)22 | PVI± roof line, mitral isthmus or CTI line | 1.1 | Eight of nine patients with HCM (88.9%) were free from AF recurrence without AADs |
| Hayashi et al (2014)23 | PVI+roof line+posterior inferior line+CTI±mitral isthmus, if persistent AF | HCM 1.5; controls 1.4 Second procedure: 47% (8) HCM, 35% (12) controls (p=0.87) | AADs used more frequently in patients with HCM (47% vs 12%, p=0.008) |
| Contreras-Valdes et al (2015)24 | PVI Ablation of sustained organised AT | HCM 1.3±0.5 Controls 1.2±0.4 (p=0.7) | Chronic AADs in 45% HCM vs 18.8% controls (p=0.007) |
| Müssigbrodt et al (2015)25 | PVI±roof line, septal line and CTI line | HCM 1.4, controls 1.1 Second procedure: five patients with HCM vs three controls Third procedure: three patients with HCM (p=0.045) | 6 of 22 (27%) patients with HCM treated with AADs vs none in non-HCM group (p=0.008) |
| Okamatsu et al (2015)26 | PVI±CTI | 1.1 Second procedure: three patients with HCM | 15 (68%) patients used concomitant AADs |
| Wen et al (2015)27 | Paroxysmal AF: PVI+CTI (if documentation of typical flutter). Persistent AF: +roof line, mitral isthmus and CTI | 1.0 | N.A. |
AADs, antiarrhythmic drugs; AF, atrial fibrillation; AT, atrial tachycardia; CFAE, complex fractionated atrial electrograms; CS, coronary sinus; CTI, cavotricuspid isthmus; HCM, hypertrophic cardiomyopathy; LA, left atrium; N.A., not available; PVI, to be interpreted as wide antral circumferential ablation, unless stated ostial PVI; PV, pulmonary vein; SVC, superior vena cava; SR, sinus rhythm; WACA, wide antral circumferential ablation.